Increased circulating levels of matrix metalloproteinase (MMP)-8, MMP-9, and pro-inflammatory markers in patients with metabolic syndrome


Autoria(s): GONCALVES, Flavia M.; JACOB-FERREIRA, Anna L. B.; GOMES, Valeria A.; CASELLA-FILHO, Antonio; CHAGAS, Antonio C. P.; MARCACCINI, Andrea M.; GERLACH, Raquel F.; TANUS-SANTOS, Jose E.
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

19/10/2012

19/10/2012

2009

Resumo

Background: Metabolic syndrome (MetS) predisposes to cardiovascular complications. Increased concentrations of pro-inflammatory mediators and imbalanced concentrations of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) may reflect the pathophysiology of MetS. We compared the circulating levels of MMPs, TIMPs, and inflammatory mediators in MetS patients with those found in healthy controls. Methods: We studied 25 healthy subjects and 25 MetS patients. The plasma levels of pro-MMP-2 and pro-MMP-9 were determined by gelatin zymography. The plasma concentrations of MMP-8, MMP-3, TIMP-1, TIMP-2, monocyte chemoattractant protein-1 (MCP-1), interleukin-6 (IL-6), intercellular adhesion molecule (sICAM-1), and sP-selectin were measured by ELISA kits. Results: We found higher sP-selectin, sICAM-1, MCP-1, and IL-6 (all P<0.05) concentrations in MetS patients compared with healthy controls. No differences in pro-MMP-2, MMP-3, and TIMP-2 levels were found (all P>0.05). However, we found higher pro-MMP-9, MMP-8. and TIMP-1 levels in MetS patients compared with healthy controls (all P<0.05). Conclusions: Patients with MetS have increased circulating concentrations of pro-MMP-9, MMP-8, and TIMP-1 that are associated with increased concentrations of pro-inflammatory mediators and adhesion molecules. These findings suggest that MMPs may have a role in the increased cardiovascular risk of MetS patients. Pharmacological interventions targeting MMPs, especially MMP-9 and MMP-8 deserve further investigation in MetS patients. (C) 2009 Elsevier B.V. All rights reserved.

Fundacao de Amparo A Pesquisa do Estado de Sao Paulo (FAPESP)

Conselho Nacional de Desenvolvimento Cientifico, e Tecnologico, (CNPq)

Coordenadoria de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)

Identificador

CLINICA CHIMICA ACTA, v.403, n.1/Fev, p.173-177, 2009

0009-8981

http://producao.usp.br/handle/BDPI/26251

10.1016/j.cca.2009.02.013

http://dx.doi.org/10.1016/j.cca.2009.02.013

Idioma(s)

eng

Publicador

ELSEVIER SCIENCE BV

Relação

Clinica Chimica Acta

Direitos

restrictedAccess

Copyright ELSEVIER SCIENCE BV

Palavras-Chave #Inflammatory markers #Matrix metalloproteinases #Metabolic syndrome #Tissue inhibitors of metalloproteinases #RENOVASCULAR HYPERTENSIVE-RATS #URBAN-RURAL EPIDEMIOLOGY #CORONARY-ARTERY-DISEASE #NITRIC-OXIDE FORMATION #CARDIOVASCULAR-DISEASE #VASCULAR DYSFUNCTION #INSULIN-RESISTANCE #TISSUE INHIBITOR #PLASMA MATRIX-METALLOPROTEINASE-9 #HEALTHY-SUBJECTS #Medical Laboratory Technology
Tipo

article

original article

publishedVersion